U.S. regulators have warned Johnson & Johnson unit Janssen Pharmaceutica that a letter sent to doctors about its Risperdal drug to treat schizophrenia and bipolar mania is misleading. In a warning disclosed on Tuesday, the Food and Drug Administration told Janssen that its November letter failed to disclose information added to Risperdal’s labeling about excess blood sugar and diabetes and minimized the risk of serious events including coma and even death. The FDA also said the letter fails to recommend regular testing for diabetes and “misleadingly claims that Risperdal is safer than other atypical antipsychotics.”


Comments


View Comments / Leave a Comment

This post currently has 2 comments.
You can read the comments or leave your own thoughts.


    Last reviewed: By John M. Grohol, Psy.D. on 27 Apr 2004
    Published on PsychCentral.com. All rights reserved.

APA Reference
Grohol, J. (2004). J&J Warned on Claims About Antipsychotic Drug. Psych Central. Retrieved on May 26, 2013, from http://psychcentral.com/blog/archives/2004/04/27/jj-warned-on-claims-about-antipsychotic-drug/

 

Recent Comments
  • Ellen: For people whose pets provide emotional support. Many believe that these benefits constitute “service...
  • Ellen: For Paul, you can always bring a pup in to train and incorporate into your pack. Your older dog will be a good...
  • beans: Hi. I have a black lab, a seeing eye dog, the first dog I have owned and taken care of by myself. I went to...
  • Betty: Very intresting,i learnt alot,thnk u
  • Joanna: I think that may work well with extroverts, but not so much with introverts who observe more than their...
Subscribe to Our Weekly Newsletter


Find a Therapist


Users Online: 10094
Join Us Now!